WHY IS IT ESSENTIAL TO KEEP THE PAP?

BECAUSE THEY’RE WORTH IT.

1 in 5 women with cervical cancer were missed by screening with HPV-Alone.1 Pap + HPV (co-testing) empowers you to do everything you can to protect the health of your patients.

LEARN MORE

WHY IS IT ESSENTIAL TO KEEP THE PAP?

BECAUSE THEY’RE WORTH IT.

1 in 5 women with cervical cancer were missed by screening with HPV-Alone.1,2* Pap + HPV (co-testing) empowers you to do everything you can to protect the health of your patients.

LEARN MORE

Leading cervical cancer screening

For over 20 years, Hologic has been at the forefront of cervical cancer screening. Pap and human papillomavirus (HPV) testing are an essential component of our efforts in women’s health. With more than 650 million tests performed worldwide2, our ThinPrep® Pap test has become the most widely used liquid-based cytology test2—helping healthcare providers detect the presence of abnormal cervical cells.3 While other HPV assays target DNA, our Aptima® HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease. Furthermore, our Aptima HPV 16 18/45 genotype assay allows for the detection of HPV types 16, 18 and 45, which together are associated with over 75% of all cancers and 94% of adenocarcinomas.4

Hologic’s Offerings

Our specialized suite of testing tools lead the way in creating a brighter future for women’s healthcare.

ThinPrep® Pap Test

Aptima® HPV test

Aptima® HPV 16/18/45 genotype test

Know the facts

The Pap test has been the most successful cancer screening program in history.5
The rate of cervical cancer, which was a leading cause of death among women, has fallen by more than 70 percent since the Pap test was introduced over 50 years ago.6 Previously, cervical cancer was the leading cause of cancer death in women, but now it is the fifteenth most frequent.
Graph_1
Cervical cancer is no longer decreasing.7
Graph_2
Regardless of the algorithm, the collection method is the same.

The difference is in the results – with HPV-Alone*, you will receive less information with the same collection.

Samples may be collected in FDA approved liquid based cytology medium such as ThinPrep® Pap Test.

Is this the right time to make more drastic changes to screening?

“At no point in the publications describing the new guidelines [2012 consensus guidelines] it is acknowledged that we are now recommending more cancer and more death from cancer than the previously recommended 3-year cotesting provides, and that we are doing so presumably for the purpose of avoiding a cervical treatment that is not associated with detectable increased mortality.”

- Kinney W, et al.⁸

Choose Pap + HPV

Recent publications representative of US clinical practice showed
Pap + HPV (co-testing) misses the fewest cancers/precursors to cancer:

Recent publications representative of US clinical practice show Pap + HPV (co-testing) misses the fewest cancers/precursors to cancer:

Key study from 20159
Graph_4
Graph_5
Key study from 201810
Graph_4
Graph_5
Key study from 20201
Graph_4
Graph_5

Don’t sacrifice

Studies demonstrated the contribution of cytology at detecting cervical cancer cases.

Comparison of three longitudinal co-testing studies.

SS-00946-001 Rev.001 Quest Infographic_R1.00

Kaiser Permanente Northern California (KPNC): Regional laboratory and Integrated Delivery Network
Quest Diagnostics: National reference laboratory
University of Pittsburgh Medical Center (UPMC): Large academic medical center

increase-in-cytology-distributiom-img
Several clinical studies confirm screening with HPV-Alone* missed cervical cancer.
Proportion of HPV Negative Cancer Cases. 1,9,10,12-16
This chart is a representation of clinical data from multiple published sources. The clinical studies represented within these sources were conducted using different study designs with various assays.

“Liquid based cytology (LBC) enhanced co-testing detection of cervical cancer … to a greater extent than previously reported with conventional Pap smear and HPV co-testing.”

Austin RM, et al.¹⁰

ACOG guidelines recommend co-testing as the preferred method

ACOG recommends that for women ages 30-65 years old: 17
Hologic_Icon_1
Co-testing with cervical cytology and high-risk HPV testing every 5 years is preferred
Hologic_Icon_2
Screening with cervical cytology alone every 3 years is acceptable
Hologic_Icon_3
High-risk HPV-Alone* can be considered as an alternative screening strategy

In many cases, co-testing is covered by the Affordable Care Act.

For patients, this may mean18 :
Hologic_Icon_1
No co-pay
Hologic_Icon_2
No deductible
Hologic_Icon_3
No out-of-pocket cost
Patients should consult their healthcare plans to verify coverage.
Learn why every woman is worth two tests at hologicwomenshealth.com/cervicalhealth

Co-testing adoption rates at an all time high

Because Pap + HPV together (co-testing) provides more protection against CIN3+ and cervical cancer than screening with either HPV or Pap-alone, co-testing has become the most widely used screening method by ObGyns in the United States.19
Cervical Cancer Screening Method in the US for women ages 30 to 65

Remaining 18% is primarily Pap-based testing

†Based on a 2019 survey of ObGyns

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?